Atlas Trials

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Clinical trial NCT05197075 · COMPLETED

Trial details

NCT number
NCT05197075
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Human Immunodeficiency Virus (HIV)
Start date
2022-08-03
Primary completion
2022-09-23
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.